Osteoporosis meaning ‘porous bone’ is a progressive disease that occurs when the body loses bone mass and increases bone fragility and susceptibility to fractures. Osteoporosis affects up to 50 per cent of women and 25 per cent of males over the age of 50 years. An estimated 300,000 people in Ireland have osteoporosis.
In the general population bone mass increases through childhood, peaks in adolescence, remains relatively constant in early/late adulthood and declines in old age. The adult skeleton is continually re-modelling through bone resorption followed by bone formation. Osteoclasts are involved in bone resorption and osteoblasts are involved in bone formation.
The rate of re-modelling is affected by many factors including
sex hormones, vitamin D and parathyroid hormone. When balance is altered for various reasons this can then result in greater bone removal than replacement which leads to the development of osteoporosis.
Osteoporosis is often considered a ‘silent disease’ with many patients not aware they have the condition until they have a fracture. Due to the weakened bone condition fractures can occur from mechanical forces that would not normally lead to a fracture, eg, a simple trip.
Approximately 53 per cent of patients who suffer a hip fracture can no longer live independently and 28.7 per cent will die within 12 months of the fracture. In Ireland, €402 million per year is spent on treating a fall and fracture in the elderly. Therefore it is important to identify patients at risk, and diagnose osteoporosis early to try to counteract the progression of the condition.
Osteopaenia is considered the early stage bone disease and places a person at a higher risk of developing osteoporosis.
Some risk factors for osteoporosis include:
The following are some examples of medications which are also associated with osteoporosis:
Osteoporosis can be diagnosed by the presence of fragility fractures, measurement of BMD or less commonly by bone biopsy. Early diagnosis is key to optimum results. Dual-energy x-ray absorptiometry (DXA) scans are the gold standard for diagnosing osteoporosis. A DXA scan applied to the femoral neck is the preferred site by the WHO and International Osteoporosis Foundation due to the higher predictive value for fracture risk.
The spine is not recommended as a suitable site for diagnosis of osteoporosis in older patients as there is a proportionally higher prevalence of degenerative changes which would inflate the BMD score, however, it is used as a site for assessing response to treatment.
BMD is used by the WHO for defining osteoporosis, as BMD correlates with bone strength and can be used as a predictor of future fracture risk. Fracture risk increases progressively as BMD decreases.
Once a BMD figure is obtained, a T-score can then be identified. A T-score is a comparison of BMD with the BMD of a healthy young adult.
The WHO categories osteoporosis and osteopaenia as the following:
Patients should be advised to adjust any modifiable risk factors such as to reduce alcohol and stop smoking. Patients should aim to reduce fracture risk factor by increasing dietary calcium and vitamin D, participate in regular weight-bearing exercise such as walking, and muscle-strengthening exercise.
Fall prevention is extremely important for these patients; ensure home environments are safe and clutter free, and appropriate footwear is recommended.
The aim of treatment is to slow down or stop bone loss, increase bone density, prevent fractures and increase a person’s quality-of-life.
Calcium and vitamin D should be recommended to all patients unless contraindicated. Some evidence suggests daily calcium intake in excess of 1,200mg may increase risk of kidney stones, cardiovascular disease and stroke, therefore calculation of daily intake, including from dietary sources, is sometimes recommended.
Bisphosphonates work by inducing apoptosis of osteoclasts, therefore inhibiting bone resorption and decrease risk of fractures.
There are many different formulations of bisphosphonates available from daily, weekly or monthly oral formulations and three-monthly or yearly IV formulations. Some bisphosphonates come in combinations with vitamin D. Alendronate, risedronate, ibandronate, and zoledronic acid are examples of bisphosphonates.
Counselling points for oral bisphosphonates:
Bisphosphonate treatment should be reviewed after five years and after three years for zoledronic acid. Limitations to bisphosphonate therapy includes: Severe renal impairment (crcl below 30-35ml/min), hypocalcaemia, oesophageal abnormalities, hiatus hernia, and gastritis.
Osteonecrosis of the jaw is a risk factor for bisphosphonate therapy, but is a greater risk for IV bisphosphonates in the treatment of cancer. Risk factors for developing osteonecrosis of the jaw should be considered including: Potency of bisphosphonate, route of administration, cumulative dose, duration and history of dental disease.
Denosumab is a monoclonal antibody that binds to the receptor on the osteoclast surface which inhibits the maturation of the osteoclast, therefore protecting the bone from degradation, preventing bone loss and osteoporosis. It is given as a six-monthly subcutaneous injection (Prolia).
It is also considered useful for patients unable to tolerate bisphosphonates.
Hypocalcaemia is a risk for patients treated with denosumab, therefore vitamin D deficiency should be explored prior to treatment. A 50,000-to-100,000 unit oral loading dose of vitamin D should be advised for those with vitamin D deficiency prior to denosumab therapy and adequate intake of calcium with vitamin D is important. Calcium levels should be checked prior to each denosumab dose and within two weeks of initial dose to patients predisposed to hypocalcaemia.
HRT – some HRT comprising of oestrogen or oestrogen plus progestogen are approved for prevention of osteoporosis in postmenopausal women and have been shown to reduce fractures with low bone density. However, the increased venous thromboembolism (VTE) risk and contraindication in breast cancer means it is restricted to younger postmenopausal women
Teriparatide, which is recombinant human parathyroid hormone (PTH) 1-34, stimulates osteoblastic activity. It is given as a subcutaneous injection 20μg/day for 24 months and the course cannot be repeated.
It is recommended for those with severe osteoporosis. Bone mineral content is lost quickly on cessation of therapy and therefore it is important to commence an anti-resorptive agent when stopping therapy.
Selective oestrogen-receptor modulators (SERMs), eg, raloxifene, are medications that exhibit oestrogen receptor agonist activity and maintain bone density and reduce fracture rates. Raloxifene is taken as a 60mg oral tablet daily.
It has some limitations to use as it is contraindicated in women of childbearing potential, history of VTE, hepatic and severe renal impairment.
Calcitriol is the active form of vitamin D and can be used for treatment of established postmenopausal osteoporosis at a dose of 0.25 nanograms twice daily. It inhibits bone resorption and reduces fracture risk.
Strontium ranelate reduces bone resorption, prevents bone loss and increases bone formation and BMD through formation of new normal strong bone. It comes as a 2g sachet, which is taken daily with water. Calcium-containing products must be avoided two hours before and after dosing due to the interaction with calcium.
References on request
Protecting osteoporosis patients during Covid-19 by Priscilla Lynch
The key message of the recent 2020 Irish Osteoporosis Society (IOS) annual conference was continuation of care for osteoporosis patients during the Covid-19 pandemic and the importance of fracture prevention efforts.
Many patients and healthcare professionals themselves are not fully cognisant of the risks of ‘drug holidays’ for osteoporosis therapies, which anecdotally seem to have increased during the pandemic, the conference heard.
A number of speakers warned against taking drug holidays for the stronger osteoporosis therapies in particular, such as the human monoclonal antibody denosumab, which is used for the treatment of osteoporosis and treatment-induced bone loss. The six-monthly subcutaneous injection inhibits osteoclast bone resportion, thereby decreasing the release of calcium from bone into the blood stream, and is a very potent treatment but its effects can wear off very quickly if stopped suddenly, rapidly increasing fracture risks.
The conference heard powerful testimonies from a number of Irish female osteoporosis patients about their negative experiences of drug holidays (fractures, falls, pain and disability) and the impact of late diagnosis and inadequate osteoporosis treatment.
Speaking to the Medical Independent, IOS President Prof Moira O’Brien said she would never put one of her patients on a drug holiday, and voiced concern about osteoporosis patients “slipping through the cracks” during the Covid-19 pandemic. She called on all healthcare professionals to ensure that their patients continue to receive appropriate care and treatments for osteoporosis, and that suspected cases continue to be referred for DXA scans and full assessments.
High stress levels raise cortisol levels and cause bone loss. “This is very important to remember and very few people realise it,” Prof O’Brien said, noting that the pandemic has increased stress levels among the population.
The IOS helpline has received an increased number of calls in recent months from osteoporosis patients who report not attending their medical professionals for follow ups or to receive treatment and scans as they are frightened of getting Covid-19, and are thus increasing their fracture risks.
Prof O’Brien advised that the IOS website contains a number of useful tools and educational resources for both healthcare professionals and patients, and called on all healthcare professionals to refer their patients to the site,
As early and pragmatic adopters of new technologies, Irish hospitals can become centres of excellence when...
The Judge's report proposes that a Tribunal be established under legislation to hear and determine claims...
In December, the HSE released part of an external review into the case of 'Brandon', a...
The evidence on doctor burnout “should scare us and concern us”, the Director of the RCSI...
A review of public health governance structures and addressing “longstanding” IT infrastructure...